We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

23Andme Holding Co (ME) USD0.0001 A

Sell:$0.52 Buy:$0.53 Change: $0.0253 (4.97%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0253 (4.97%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.0253 (4.97%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including information on customers’ genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. The Therapeutics business segment focuses on the use of genetic insights from databases of genetic and phenotypic information to develop novel therapies to improve patients’ lives. The Therapeutics segment consists of out-licensing of intellectual property associated with identified drug targets and expenses related to therapeutic product candidates.

Contact details

349 Oyster Point Boulevard
United States
+1 (650) 9386300

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$252.71 million
Shares in issue:
482.92 million
Health Care Services
United States
US dollar

Key personnel

  • Anne Wojcicki
    Chairman of the Board, President, Chief Executive Officer, Co-Founder
  • Joe Selsavage
    Interim Chief Financial Officer, Chief Accounting Officer
  • Kathy Hibbs
    Chief Administrative Officer, Company Secretary
  • Guy Chayoun
    General Counsel, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.